Literature DB >> 8599221

Selective expression of a subset of measles virus receptor-competent CD46 isoforms in human brain.

C J Buchholz1, D Gerlier, A Hu, T Cathomen, M K Liszewski, J P Atkinson, R Cattaneo.   

Abstract

The human cell surface protein CD46 is the main measles virus (MV) receptor. We analyzed the CD46 isoforms expressed in the brain of three patients who died with persistent MV infections and in an unaffected brain. Complete CD46 cDNAs were produced and found to code exclusively for CD46 isoforms with cytoplasmic tail 2. Selective expression of tail 2 isoforms was shown in a second control brain by Western blots with antibodies specific for each of the cytoplasmic tails. Binding of purified MV particles and virus-dependent cell fusion were tested after transient expression of brain-derived CD46 proteins in mouse cells. All the brain-derived proteins mediated MV binding and virus-dependent fusion. Isoforms containing both serine/threonine/proline (STP)-rich domains were more active in virus binding, whereas isoforms with only one STP domain were more efficient in mediating fusion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8599221     DOI: 10.1006/viro.1996.0122

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

Review 1.  Virus receptors in the human central nervous system.

Authors:  B Schweighardt; W J Atwood
Journal:  J Neurovirol       Date:  2001-06       Impact factor: 2.643

2.  Productive measles virus brain infection and apoptosis in CD46 transgenic mice.

Authors:  A Evlashev; E Moyse; H Valentin; O Azocar; M C Trescol-Biémont; J C Marie; C Rabourdin-Combe; B Horvat
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 3.  CD46 processing: a means of expression.

Authors:  Siobhan Ni Choileain; Anne L Astier
Journal:  Immunobiology       Date:  2011-07-13       Impact factor: 3.144

4.  The SI strain of measles virus derived from a patient with subacute sclerosing panencephalitis possesses typical genome alterations and unique amino acid changes that modulate receptor specificity and reduce membrane fusion activity.

Authors:  Fumio Seki; Kentaro Yamada; Yuichiro Nakatsu; Koji Okamura; Yusuke Yanagi; Tetsuo Nakayama; Katsuhiro Komase; Makoto Takeda
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

5.  Molecular cloning of membrane cofactor protein (MCP; CD46) on B95a cell, an Epstein-Barr virus-transformed marmoset B cell line: B95a-MCP is susceptible to infection by the CAM, but not the Nagahata strain of the measles virus.

Authors:  Y Murakami; T Seya; M Kurita; A Fukui; S Ueda; S Nagasawa
Journal:  Biochem J       Date:  1998-03-15       Impact factor: 3.857

6.  Membrane cofactor protein (MCP; CD46) expression in transgenic mice.

Authors:  C Kemper; M Leung; C B Stephensen; C A Pinkert; M K Liszewski; R Cattaneo; J P Atkinson
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

7.  CD46 short consensus repeats III and IV enhance measles virus binding but impair soluble hemagglutinin binding.

Authors:  P Devaux; C J Buchholz; U Schneider; C Escoffier; R Cattaneo; D Gerlier
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

8.  Cell entry by measles virus: long hybrid receptors uncouple binding from membrane fusion.

Authors:  C J Buchholz; U Schneider; P Devaux; D Gerlier; R Cattaneo
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  Structure of the extracellular portion of CD46 provides insights into its interactions with complement proteins and pathogens.

Authors:  B David Persson; Nikolaus B Schmitz; César Santiago; Georg Zocher; Mykol Larvie; Ulrike Scheu; José M Casasnovas; Thilo Stehle
Journal:  PLoS Pathog       Date:  2010-09-30       Impact factor: 6.823

10.  Measles virus spread and pathogenesis in genetically modified mice.

Authors:  B Mrkic; J Pavlovic; T Rülicke; P Volpe; C J Buchholz; D Hourcade; J P Atkinson; A Aguzzi; R Cattaneo
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.